NO20072470L - Malariaigangsetter/forsterkervaksine - Google Patents

Malariaigangsetter/forsterkervaksine

Info

Publication number
NO20072470L
NO20072470L NO20072470A NO20072470A NO20072470L NO 20072470 L NO20072470 L NO 20072470L NO 20072470 A NO20072470 A NO 20072470A NO 20072470 A NO20072470 A NO 20072470A NO 20072470 L NO20072470 L NO 20072470L
Authority
NO
Norway
Prior art keywords
initiator
malaria
vaccine
amplifier
regimens
Prior art date
Application number
NO20072470A
Other languages
English (en)
Inventor
Joseph D Cohen
Maria Pau
Jaap Goudsmit
Patrice M Dubois
V Ann Stewart
Donald Heppner
Original Assignee
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Army filed Critical Us Army
Publication of NO20072470L publication Critical patent/NO20072470L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Oppfinnelsen angår nye vaksineregimer hvor spesifikke igangsetter-/forsterkertegimer anvendes ved å bruke lavnøytraliserte rekombinante adenoviralvektorer som inneholder nukleinsyrer som koder for antigener fra Plasmodium falciparum samt rensede rekombinante proteinvaksiner så som RTS,S i sammenheng med passene adjuvanter.
NO20072470A 2004-10-14 2007-05-14 Malariaigangsetter/forsterkervaksine NO20072470L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US61905604P 2004-10-14 2004-10-14
EP04105035 2004-10-14
PCT/EP2005/055209 WO2006040334A1 (en) 2004-10-14 2005-10-13 Malaria prime/boost vaccines

Publications (1)

Publication Number Publication Date
NO20072470L true NO20072470L (no) 2007-07-16

Family

ID=34929701

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072470A NO20072470L (no) 2004-10-14 2007-05-14 Malariaigangsetter/forsterkervaksine

Country Status (24)

Country Link
US (3) US20080131461A1 (no)
EP (1) EP1802336B1 (no)
JP (1) JP5108521B2 (no)
KR (1) KR20070104881A (no)
CN (1) CN101068568B (no)
AT (1) ATE523205T1 (no)
AU (1) AU2005293572B2 (no)
BR (1) BRPI0518146A (no)
CA (1) CA2582455A1 (no)
CY (1) CY1112749T1 (no)
DK (1) DK1802336T3 (no)
EA (1) EA016648B1 (no)
ES (1) ES2371175T3 (no)
HR (1) HRP20110786T1 (no)
IL (2) IL182357A0 (no)
MA (1) MA29212B1 (no)
MX (1) MX2007004031A (no)
NO (1) NO20072470L (no)
NZ (1) NZ583291A (no)
PL (1) PL1802336T3 (no)
PT (1) PT1802336E (no)
RS (1) RS52187B (no)
SI (1) SI1802336T1 (no)
WO (1) WO2006040334A1 (no)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
US6929946B1 (en) * 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US20050002958A1 (en) * 1999-06-29 2005-01-06 Smithkline Beecham Biologicals Sa Vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
JP4480398B2 (ja) * 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
WO2004055187A1 (en) 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ES2371175T3 (es) * 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
US20090110695A1 (en) * 2006-03-27 2009-04-30 Menzo Jans Emko Havenga Compositions Comprising a Recombinant Adenovirus and an Adjuvant
US9717788B2 (en) 2007-03-02 2017-08-01 Glaxosmithkline Biologicals Sa Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant
AU2008288508B2 (en) 2007-08-13 2014-05-01 Glaxosmithkline Biologicals S.A. Vaccines
PT2220242T (pt) 2007-11-28 2017-04-03 Univ Pennsylvania Adenovírus símio da subfamília b sadv-28,27,-29,-32,-33 e -35 e suas utilizações
KR101761691B1 (ko) 2007-11-28 2017-07-26 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 유인원 ｅ 아데노바이러스 ｓａｄｖ-39, -25.2, -26, -30, -37, 및 -38
CA2707245A1 (en) * 2007-12-06 2009-06-11 Glaxosmithkline Biologicals S.A. Vaccine
EP2250255A2 (en) 2008-03-04 2010-11-17 The Trustees of the University of Pennsylvania Simian adenoviruses sadv-36,-42.1, -42.2, and -44 and uses thereof
EP2346523A4 (en) * 2008-10-01 2014-12-31 Us Health MULTICOMPONENT VACCINE AGAINST MALARIA INDUCING SUSTAINABLE IMMUNE RESPONSES AGAINST PLASMODIUM
WO2010060719A1 (en) 2008-11-03 2010-06-03 Crucell Holland B.V. Method for the production of adenoviral vectors
AU2010272685B2 (en) 2009-07-16 2015-02-26 Crucell Holland B.V. Production of polio virus at high titers for vaccine production
MX354752B (es) * 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
PL2655604T3 (pl) * 2010-12-14 2019-02-28 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Szczepionki adenowirusowe serotyp 26 i serotyp 35 przeciwko filowirusom
AU2012243039B2 (en) * 2011-04-08 2017-07-13 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
NZ717682A (en) 2012-02-16 2017-10-27 Vlp Therapeutics Llc Virus like particle composition
SG10201609511XA (en) 2012-05-18 2016-12-29 Univ Pennsylvania Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
CN105431535A (zh) * 2013-06-03 2016-03-23 Vlp治疗有限责任公司 疟疾疫苗
TWI676636B (zh) 2013-07-12 2019-11-11 Ｖｌｐ醫療股份有限公司 包含ｐｄ－１抗原或ｐｄ－１配體抗原的類病毒粒子
US9321834B2 (en) 2013-12-05 2016-04-26 Leidos, Inc. Anti-malarial compositions
GB201405921D0 (en) 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
NZ727020A (en) 2014-06-26 2022-02-25 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10385101B2 (en) 2014-08-08 2019-08-20 Vlp Therapeutics, Llc Virus like particle comprising modified envelope protein E3
CN106795513B (zh) 2014-08-08 2021-06-11 Vlp治疗公司 包含修饰的包膜蛋白e3的病毒样颗粒
CN106687590B (zh) 2014-09-11 2021-08-03 Vlp治疗公司 黄热病毒病毒样颗粒
WO2016059911A1 (ja) * 2014-10-17 2016-04-21 国立大学法人金沢大学 マラリアワクチン
US20210260176A1 (en) * 2017-03-30 2021-08-26 United States Of America As Represented By The Secretary Of The Navy Methods and Compositions for Vaccinating Against Malaria
SG11202005792RA (en) 2017-12-20 2020-07-29 Vlp Therapeutics Llc Alphavirus replicon particle
CA3091969A1 (en) * 2018-02-22 2019-08-29 Turnstone Limited Partnership Oncolytic viruses as adjuvants
CN113453707A (zh) * 2018-12-21 2021-09-28 库瑞瓦格股份公司 用于疟疾疫苗的rna
CN113966228A (zh) * 2019-06-11 2022-01-21 葛兰素史密斯克莱生物公司 黏膜疫苗配制剂
KR20220160042A (ko) 2020-03-27 2022-12-05 스벤스카 박신파브리셴 프로둑숀 아베 코로나바이러스의 치료 및 예방을 위한 조성물 및 방법
EP4135847A4 (en) 2020-04-17 2024-05-15 VLP Therapeutics, Inc. Coronavirus vaccine
WO2021221127A1 (en) 2020-04-30 2021-11-04 Vlp Therapeutics, Inc. Cytokine immunotherapy
WO2023056284A1 (en) 2021-09-29 2023-04-06 Svenska Vaccinfabriken Produktion Ab Compositions and methods for treating and preventing coronavirus infection

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306625B1 (en) * 1988-12-30 2001-10-23 Smithkline Beecham Biologicals, Sa Method for obtaining expression of mixed polypeptide particles in yeast
CA2123612C (en) * 1991-11-16 2002-06-25 Michel De Wilde Hybrid protein between cs from plasmodium and h bsag
FR2763959A1 (fr) * 1997-06-02 1998-12-04 Transgene Sa Nouveaux vecteurs adenoviraux recombinants comprenant une sequence d'epissage
US20050164386A1 (en) * 1999-04-15 2005-07-28 Uytdehaag Alphonsus G. Overexpression of enzymes involved in post-translational protein modifications in human cells
US7604960B2 (en) * 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US7527961B2 (en) * 1999-11-26 2009-05-05 Crucell Holland B.V. Production of vaccines
US7521220B2 (en) * 1999-11-26 2009-04-21 Crucell Holland B.V. Production of vaccines
US7192759B1 (en) * 1999-11-26 2007-03-20 Crucell Holland B.V. Production of vaccines
JP4480398B2 (ja) * 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
WO2004037294A2 (en) * 2002-10-23 2004-05-06 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) * 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US7491395B2 (en) * 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
WO2004055187A1 (en) * 2002-12-17 2004-07-01 Crucell Holland B.V. Recombinant viral-based malaria vaccines
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
ES2371175T3 (es) * 2004-10-14 2011-12-28 Crucell Holland B.V. Vacunas de sensibilización/refuerzo de malaria.
KR101255861B1 (ko) * 2004-11-11 2013-04-17 크루셀 홀란드 비.브이. 사스-코로나바이러스에 대한 조성물 및 그것의 용도

Also Published As

Publication number Publication date
CN101068568A (zh) 2007-11-07
IL182357A0 (en) 2007-07-24
AU2005293572B2 (en) 2011-08-04
NZ583291A (en) 2011-06-30
SI1802336T1 (sl) 2012-01-31
US20080131461A1 (en) 2008-06-05
US20120014994A1 (en) 2012-01-19
EA016648B1 (ru) 2012-06-29
IL214460A0 (en) 2011-09-27
AU2005293572A1 (en) 2006-04-20
DK1802336T3 (da) 2011-11-14
US20090285879A1 (en) 2009-11-19
MA29212B1 (fr) 2008-02-01
EP1802336B1 (en) 2011-09-07
RS52187B (sr) 2012-10-31
HRP20110786T1 (hr) 2011-12-31
WO2006040334A1 (en) 2006-04-20
HK1100121A1 (en) 2007-09-07
PT1802336E (pt) 2011-11-15
ATE523205T1 (de) 2011-09-15
EP1802336A1 (en) 2007-07-04
CY1112749T1 (el) 2016-02-10
JP5108521B2 (ja) 2012-12-26
EA200700849A1 (ru) 2007-10-26
PL1802336T3 (pl) 2012-03-30
CA2582455A1 (en) 2006-04-20
KR20070104881A (ko) 2007-10-29
CN101068568B (zh) 2012-09-26
BRPI0518146A (pt) 2008-10-28
MX2007004031A (es) 2007-11-08
JP2008516926A (ja) 2008-05-22
ES2371175T3 (es) 2011-12-28

Similar Documents

Publication Publication Date Title
EA200700849A1 (ru) Первичная/бустерная противомалярийная вакцина
NO20090194L (no) Rekombinant viral vaksine
SG156535A1 (en) Recombinant viral-based malaria vaccines
CY1110793T1 (el) Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα
EA201001491A1 (ru) Репликационно-дефектные вакцины и вакцинные векторы против флавивирусов
DK1487485T3 (da) Imidazoquinolinadjuvanser til DNA-vacciner
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
ECSP088231A (es) Vacunas de malaria a base de vectores adenovirales
ATE494906T1 (de) Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna
MX362698B (es) Metodo novedoso y composiciones.
CO6150189A2 (es) Vacunas para malaria
ATE461710T1 (de) Nipah-virus-impfstoffe
WO2011057254A3 (en) Simian adenoviral vector-based vaccines
DK1536015T3 (da) Promotorer til ekspression i modificeret vacciniavirus Ankara
WO2008086386A8 (en) Adenoviral vector-based malaria vaccines
WO2007016598A3 (en) Influenza vaccine compositions and methods of use thereof
MX2010007876A (es) Vectores virales recombinantes y composicion de vacuna para leishmaniasis.
EP1816203A4 (en) FOR CORONAVIRUS-SIMILAR PARTICLES CODING EXPRESSION VECTOR
ATE455854T1 (de) Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria
WO2008118936A3 (en) Method of elicting immune response with a modified mva viral hiv-1 vector
WO2007104263A8 (zh) 一种乙型肝炎病毒疫苗增效蛋白及其基因
NO20070345L (no) Anvendelse av DNA molekyl som vaksine adjuvant
WO2009079731A3 (en) Vaccine comprising toxoplasma gondii surface proteins
WO2010127420A9 (pt) Sequências geneticamente modificadas de antígenos de plasmodium vivax

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application